We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Foghorn Therapeutics Inc
3 own
2 watching
Current Price
$0
$0.02
(0.29%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
357.38M
52-Week High
18.12
52-Week Low
5.32
Average Volume
0.01M
Dividend Yield
--
P/E Ratio
--
Market Capitalization357.38M52-Week High18.1252-Week Low5.32Average Volume0.01MDividend Yield--P/E Ratio--What does the Foghorn Therapeutics Inc do?
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Foghorn Therapeutics Inc make?
News & Events about Foghorn Therapeutics Inc.
Globe Newswire
25days ago
- Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma continues to progress with initial efficacy and safety data expected in the first half of 2023 - Phase 1 dose escalation study of FHD-609, a selective degrader of BRD9, in synovial sarcoma continues to ...
Ticker Report
27days ago
Research analysts at BMO Capital Markets began coverage on shares of Foghorn Therapeutics (NASDAQ:FHTX Get Rating) in a research report issued on Thursday, The Fly reports. The brokerage set an outperform rating and a $20.00 price target on the stock. BMO Capital Markets’...
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Adrian Gottschalk, President and Chief ...
PR Newswire
3 months ago
Alltrna Appoints Caroline Khrer, Ph.D., Vice President, Discovery Platform Alltrna Appoints Caroline Khrer, Ph.D., Vice President, Discovery Platform PR Newswire CAMBRIDGE, Mass., Oct. 17, 2022 Dr. Khrer has more than 25 years of RNA research and development experience, including pioneering novel...
Globe Newswire
9 months ago
CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced preclinical data ...
Frequently Asked Questions
Frequently Asked Questions
What is Foghorn Therapeutics Inc share price today?
Can Indians buy Foghorn Therapeutics Inc shares?
How can I buy Foghorn Therapeutics Inc shares from India?
Can Fractional shares of Foghorn Therapeutics Inc be purchased?
What are the documents required to start investing in Foghorn Therapeutics Inc stocks?
What is today’s traded volume of Foghorn Therapeutics Inc?
What is today’s market capitalisation of Foghorn Therapeutics Inc?
What is the 52-Week High and Low Range of Foghorn Therapeutics Inc?
What percentage is Foghorn Therapeutics Inc down from its 52-Week High?
What percentage is Foghorn Therapeutics Inc up from its 52-Week Low?
Current Price
$0
$0.02
(0.29%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.